MCG Health Releases 22nd Edition of Evidence-Based Care Guidelines

Share Article

Industry leader of informed care strategies further expands its content for healthcare professionals



The 22nd edition reflects not only the voice of our customers who are asking for specific guidance based on real-world evidence but also the needs of today’s diverse patient populations.

MCG Health, part of the Hearst Health network and a leading provider of informed care strategies, announced today the release of its 22nd edition of evidence-based care guidelines. The updated content includes specific support to address many of the healthcare industry’s most important challenges such as the expanding Medicare population, the national opioid epidemic, and the complexity of genetic testing. In addition, new clinical guidance has been added for specialty medications, chronic care conditions, and ambulatory procedures. MCG Cite and Indicia software solutions, which allow interactive access to the guideline content, will be updated to version 10.0 in the upcoming weeks.

Since 1990, MCG has led the healthcare industry in continually reviewing new and updated clinical research and scholarly articles and applying that knowledge to its extensive evidence base. Over the past year, MCG teams of physician and nurse editors reviewed an unprecedented 316,785 references, incorporating over 6,900 new unique citations into the MCG care guidelines. The updates bring the unique citations in the MCG care guidelines to nearly 43,000.

With the Centers for Medicare and Medicaid Services (CMS) expecting a 9% increase in Medicare Advantage enrollment in 2018, MCG has also incorporated a new Medicare Compliance solution into its robust catalog of content. This new volume contains all appropriate Medicare National Coverage Determinations (NCDs) thereby offering MCG clients who license the material quicker access to Medicare criteria and increased workflow efficiency.

In response to the ongoing opioid crisis, a U.S. public health emergency which has claimed thousands of American lives, MCG enhanced its opioid-related content with new referral management guidance, as well as a new opioid risk tool to help identify potential dependency issues. This additional support for pain management populations is included in both the Ambulatory Care and Behavioral Health Care volumes.

With the 22nd edition, MCG also augments its support for the complete arc of care by including new patient-facing education material, as well as “Social Determinants of Health” assessments to account for needs that fall outside of a hospital setting. These tools are designed to evaluate the interweaving social and economic factors which disproportionately affect the chronically ill as well as those transitioning between care settings.

Of the 22nd edition, Jon Shreve, President and CEO of MCG says, “MCG continues to lead the industry by facing healthcare’s many challenges with specific care guidance solutions designed to lead both providers and health plans to proactively do what is right for the patient.” He concludes, “The 22nd edition reflects not only the voice of our customers who are asking for specific guidance based on real-world evidence but also the needs of today’s diverse patient populations. These are patients who are our friends and family, our neighbors and coworkers, who now more than ever need healthcare guided by vetted clinical wisdom.”

About MCG
MCG, part of the Hearst Health network, helps healthcare organizations implement informed care strategies that proactively and efficiently move people toward health. MCG’s transparent assessment of the latest research and scholarly articles, along with our own data analysis, gives patients, providers, and payers the vetted information they need to feel confident in every care decision, in every moment. For more information visit or follow our Twitter handle at @MCG_Health.

About Hearst Health
The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MedHOK, Hearst Health Ventures and the Hearst Health Innovation Lab ( Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85 percent of discharged patients, 205 million insured individuals, 70 million home health visits and 3.2 billion dispensed prescriptions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Arri Burgess
+1 206 389 5405
Email >
Follow >
MCG Health
Like >
Follow us on
Visit website